Damian Lamb

Millenium Biologix Corp. is focused on the development and commercialization of next generation, skeletal tissue regeneration products and implantable medical devices, initially targeted for orthopedic uses. These products, used alone or in combination configurations, promote the repair and natural healing of human bone and other skeletal tissues such as cartilage. Millenium's strength in developing leading treatments for regenerative medicine is based on its successful integration of three core competencies in advanced biomaterials, biologics and engineering. Its core business activities are focused on tissue engineering products, and on orthobiologicals. It was founded on April 1, 1998 and is headquartered in Kingston, ON.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto.

Part of Gilead Sciences, Inc., DELEX Therapeutics, Inc. is a Canadian company that researches and develops inhalation pain treatment products for cancer patients. The private company is based in Mississauga, Canada. DELEX Therapeutics was acquired by YM BioSciences, Inc. on May 03, 2005 for $7.60 million.

Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX.

Part of Thermo Fisher Scientific, Inc., Ionalytics Corp. designs and manufactures ion-filtering equipment and related engineering instruments. The private company is based in Ottawa, Canada. Ionalytics was acquired by Thermo Electron Corp. on August 11, 2005.

Profound Medical, Inc. develops and commercializes a unique, minimally invasive treatment for prostate cancer. Its novel technology combines Magnetic Resonance Imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. The firm deliveres via a trans-urethral approach, the technique combines the image quality of MRI with thermal ultrasound as the treatment tool. Its method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. The company was founded in June 2008 by Michael Bronskill, Rajiv Chopra and Paul Chipperton and is headquartered in Toronto, Canada.